AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $334.99 billion. The enterprise value is $389.68 billion.
| Market Cap | 334.99B |
| Enterprise Value | 389.68B |
Important Dates
The next confirmed earnings date is Wednesday, October 30, 2024, before market open.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | Oct 15, 2024 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has decreased by -0.20% in one year.
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 73.02% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 63.43 and the forward PE ratio is 16.37. AbbVie's PEG ratio is 2.07.
| PE Ratio | 63.43 |
| Forward PE | 16.37 |
| PS Ratio | 6.04 |
| Forward PS | 5.75 |
| PB Ratio | 48.95 |
| P/FCF Ratio | 18.66 |
| PEG Ratio | 2.07 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.92, with an EV/FCF ratio of 21.92.
| EV / Earnings | 73.55 |
| EV / Sales | 7.09 |
| EV / EBITDA | 14.92 |
| EV / EBIT | 22.13 |
| EV / FCF | 21.92 |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of 10.40.
| Current Ratio | 0.81 |
| Quick Ratio | 0.59 |
| Debt / Equity | 10.40 |
| Debt / EBITDA | 2.68 |
| Debt / FCF | 3.99 |
| Interest Coverage | 7.03 |
Financial Efficiency
Return on equity (ROE) is 54.26% and return on invested capital (ROIC) is 14.47%.
| Return on Equity (ROE) | 54.26% |
| Return on Assets (ROA) | 7.94% |
| Return on Capital (ROIC) | 14.47% |
| Revenue Per Employee | $1.10M |
| Profits Per Employee | $105,960 |
| Employee Count | 50,000 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 4.03 |
Taxes
In the past 12 months, AbbVie has paid $1.72 billion in taxes.
| Income Tax | 1.72B |
| Effective Tax Rate | 24.29% |
Stock Price Statistics
The stock price has increased by +31.04% in the last 52 weeks. The beta is 0.62, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +31.04% |
| 50-Day Moving Average | 194.08 |
| 200-Day Moving Average | 176.94 |
| Relative Strength Index (RSI) | 44.17 |
| Average Volume (20 Days) | 4,523,401 |
Short Selling Information
The latest short interest is 14.86 million, so 0.84% of the outstanding shares have been sold short.
| Short Interest | 14.86M |
| Short Previous Month | 19.49M |
| Short % of Shares Out | 0.84% |
| Short % of Float | 0.84% |
| Short Ratio (days to cover) | 3.15 |
Income Statement
In the last 12 months, AbbVie had revenue of $55.00 billion and earned $5.30 billion in profits. Earnings per share was $2.99.
| Revenue | 55.00B |
| Gross Profit | 38.31B |
| Operating Income | 17.61B |
| Pretax Income | 7.06B |
| Net Income | 5.30B |
| EBITDA | 26.12B |
| EBIT | 17.61B |
| Earnings Per Share (EPS) | $2.99 |
Balance Sheet
The company has $13.16 billion in cash and $70.94 billion in debt, giving a net cash position of -$57.78 billion or -$32.71 per share.
| Cash & Cash Equivalents | 13.16B |
| Total Debt | 70.94B |
| Net Cash | -57.78B |
| Net Cash Per Share | -$32.71 |
| Equity (Book Value) | 6.82B |
| Book Value Per Share | 3.84 |
| Working Capital | -8.10B |
Cash Flow
In the last 12 months, operating cash flow was $18.64 billion and capital expenditures -$858.00 million, giving a free cash flow of $17.78 billion.
| Operating Cash Flow | 18.64B |
| Capital Expenditures | -858.00M |
| Free Cash Flow | 17.78B |
| FCF Per Share | $10.07 |
Margins
Gross margin is 69.66%, with operating and profit margins of 32.01% and 9.71%.
| Gross Margin | 69.66% |
| Operating Margin | 32.01% |
| Pretax Margin | 12.85% |
| Profit Margin | 9.71% |
| EBITDA Margin | 47.49% |
| EBIT Margin | 32.01% |
| FCF Margin | 32.33% |
Dividends & Yields
This stock pays an annual dividend of $6.20, which amounts to a dividend yield of 3.27%.
| Dividend Per Share | $6.20 |
| Dividend Yield | 3.27% |
| Dividend Growth (YoY) | 4.73% |
| Years of Dividend Growth | 52 |
| Payout Ratio | 207.36% |
| Buyback Yield | 0.20% |
| Shareholder Yield | 3.46% |
| Earnings Yield | 1.60% |
| FCF Yield | 5.36% |
Analyst Forecast
The average price target for AbbVie is $199.65, which is 5.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $199.65 |
| Price Target Difference | 5.27% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 5.75% |
| EPS Growth Forecast (5Y) | 43.08% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 1.93 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.93 |
| Piotroski F-Score | 4 |